ID   PRKDC_HUMAN             Reviewed;        4128 AA.
AC   P78527; P78528; Q13327; Q13337; Q14175; Q59H99; Q7Z611; Q96SE6;
AC   Q9UME3;
DT   27-APR-2001, integrated into UniProtKB/Swiss-Prot.
DT   31-OCT-2003, sequence version 3.
DT   10-MAY-2017, entry version 189.
DE   RecName: Full=DNA-dependent protein kinase catalytic subunit;
DE            Short=DNA-PK catalytic subunit;
DE            Short=DNA-PKcs;
DE            EC=2.7.11.1;
DE   AltName: Full=DNPK1;
DE   AltName: Full=p460;
GN   Name=PRKDC; Synonyms=HYRC, HYRC1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=7671312; DOI=10.1016/0092-8674(95)90482-4;
RA   Hartley K.O., Gell D., Smith G.C.M., Zhang H., Divecha N.,
RA   Connelly M.A., Admon A., Lees-Miller S.P., Anderson C.W.,
RA   Jackson S.P.;
RT   "DNA-dependent protein kinase catalytic subunit: a relative of
RT   phosphatidylinositol 3-kinase and the ataxia telangiectasia gene
RT   product.";
RL   Cell 82:849-856(1995).
RN   [2]
RP   SEQUENCE REVISION, AND ALTERNATIVE SPLICING.
RA   Gell D., Anderson C.W.;
RL   Submitted (APR-2001) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS SER-6; ILE-333;
RP   SER-605; MET-680; SER-695; SER-1071; VAL-1314; VAL-1588; HIS-1603;
RP   VAL-2095; GLU-2702; CYS-2899; ASP-3149; SER-3201; GLU-3404; THR-3434;
RP   SER-3459; MET-3562; LEU-3836 AND VAL-3932.
RG   NIEHS SNPs program;
RL   Submitted (JUN-2003) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-1689.
RX   PubMed=11418067; DOI=10.1667/0033-7587(2001)156[0002:FMIPTG]2.0.CO;2;
RA   Anderson C.W., Dunn J.J., Freimuth P.I., Galloway A.M.,
RA   Allalunis-Turner M.J.;
RT   "Frameshift mutation in PRKDC, the gene for DNA-PKcs, in the DNA
RT   repair-defective, human, glioma-derived cell line M059J.";
RL   Radiat. Res. 156:2-9(2001).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-49.
RX   PubMed=9284934;
RA   Ladenburger E.M., Fackelmayer F.O., Hameister H., Knippers R.;
RT   "MCM4 and PRKDC, human genes encoding proteins MCM4 and DNA-PKcs, are
RT   close neighbours located on chromosome 8q12-->q13.";
RL   Cytogenet. Cell Genet. 77:268-270(1997).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1789-2203.
RC   TISSUE=Placenta;
RX   PubMed=7638222; DOI=10.1073/pnas.92.16.7515;
RA   Sipley J.D., Menninger J.C., Hartley K.O., Ward D.C., Jackson S.P.,
RA   Anderson C.W.;
RT   "Gene for the catalytic subunit of the human DNA-activated protein
RT   kinase maps to the site of the XRCC7 gene on chromosome 8.";
RL   Proc. Natl. Acad. Sci. U.S.A. 92:7515-7519(1995).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 2255-2335.
RC   TISSUE=Placenta;
RA   Abe M.;
RL   Submitted (DEC-2000) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 3199-4128 (ISOFORM 1).
RC   TISSUE=Fetal lung;
RX   PubMed=7594449;
RA   Poltoratsky V.P., Shi X., York J.D., Lieber M.R., Carter T.H.;
RT   "Human DNA-activated protein kinase (DNA-PK) is homologous to
RT   phosphatidylinositol kinases.";
RL   J. Immunol. 155:4529-4533(1995).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 3250-4128 (ISOFORM 1).
RA   Anderson C.W., Dunn J.J., Freimuth P.I.;
RT   "Sequence of the 3' segment (exons 70-86) of PRKDC, the gene for human
RT   DNA-PKcs.";
RL   Submitted (APR-2001) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 3372-4128 (ISOFORM 2).
RC   TISSUE=Brain;
RA   Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S.,
RA   Ohara O., Nagase T., Kikuno F.R.;
RL   Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   PHOSPHORYLATION OF HSPCA.
RX   PubMed=2507541;
RA   Lees-Miller S.P., Anderson C.W.;
RT   "The human double-stranded DNA-activated protein kinase phosphorylates
RT   the 90-kDa heat-shock protein, hsp90 alpha at two NH2-terminal
RT   threonine residues.";
RL   J. Biol. Chem. 264:17275-17280(1989).
RN   [12]
RP   PHOSPHORYLATION OF H1.
RX   PubMed=2247066; DOI=10.1128/MCB.10.12.6460;
RA   Carter T., Vancurova I., Sun I., Lou W., DeLeon S.;
RT   "A DNA-activated protein kinase from HeLa cell nuclei.";
RL   Mol. Cell. Biol. 10:6460-6471(1990).
RN   [13]
RP   PHOSPHORYLATION OF MYC.
RX   PubMed=1597196; DOI=10.1111/j.1432-1033.1992.tb16964.x;
RA   Iijima S., Teraoka H., Date T., Tsukada K.;
RT   "DNA-activated protein kinase in Raji Burkitt's lymphoma cells.
RT   Phosphorylation of c-Myc oncoprotein.";
RL   Eur. J. Biochem. 206:595-603(1992).
RN   [14]
RP   PHOSPHORYLATION OF SRF.
RX   PubMed=8407951;
RA   Liu S.-H., Ma J.-T., Yueh A.Y., Lees-Miller S.P., Anderson C.W.,
RA   Ng S.-Y.;
RT   "The carboxyl-terminal transactivation domain of human serum response
RT   factor contains DNA-activated protein kinase phosphorylation sites.";
RL   J. Biol. Chem. 268:21147-21154(1993).
RN   [15]
RP   PHOSPHORYLATION OF JUN.
RX   PubMed=8464713; DOI=10.1093/nar/21.5.1289;
RA   Bannister A.J., Gottlieb T.M., Kouzarides T., Jackson S.P.;
RT   "c-Jun is phosphorylated by the DNA-dependent protein kinase in vitro;
RT   definition of the minimal kinase recognition motif.";
RL   Nucleic Acids Res. 21:1289-1295(1993).
RN   [16]
RP   CLEAVAGE BY CASPASE-3.
RX   PubMed=8804412; DOI=10.1016/0014-5793(96)00842-3;
RA   Teraoka H., Yumoto Y., Watanabe F., Tsukada K., Suwa A., Enari M.,
RA   Nagata S.;
RT   "CPP32/Yama/apopain cleaves the catalytic component of DNA-dependent
RT   protein kinase in the holoenzyme.";
RL   FEBS Lett. 393:1-6(1996).
RN   [17]
RP   ALTERNATIVE SPLICING.
RX   PubMed=8917110; DOI=10.1016/0378-1119(96)00135-7;
RA   Connelly M.A., Zhang H., Kieleczawa J., Anderson C.W.;
RT   "Alternate splice-site utilization in the gene for the catalytic
RT   subunit of the DNA-activated protein kinase, DNA-PKcs.";
RL   Gene 175:271-273(1996).
RN   [18]
RP   PHOSPHORYLATION OF TP53.
RX   PubMed=9363941; DOI=10.1016/S0092-8674(00)80416-X;
RA   Shieh S.-Y., Ikeda M., Taya Y., Prives C.;
RT   "DNA damage-induced phosphorylation of p53 alleviates inhibition by
RT   MDM2.";
RL   Cell 91:325-334(1997).
RN   [19]
RP   CHARACTERIZATION, AND INTERACTION WITH CIB1.
RX   PubMed=9372844; DOI=10.1016/S0921-8777(97)00035-9;
RA   Wu X., Lieber M.R.;
RT   "Interaction between DNA-dependent protein kinase and a novel protein,
RT   KIP.";
RL   Mutat. Res. 385:13-20(1997).
RN   [20]
RP   PHOSPHORYLATION OF XRCC6.
RX   PubMed=9362500; DOI=10.1093/emboj/16.22.6874;
RA   Jin S., Weaver D.T.;
RT   "Double-strand break repair by Ku70 requires heterodimerization with
RT   Ku80 and DNA binding functions.";
RL   EMBO J. 16:6874-6885(1997).
RN   [21]
RP   PHOSPHORYLATION OF RFA2.
RX   PubMed=9139719; DOI=10.1074/jbc.272.19.12634;
RA   Niu H., Erdjument-Bromage H., Pan Z.-Q., Lee S.-H., Tempst P.,
RA   Hurwitz J.;
RT   "Mapping of amino acid residues in the p34 subunit of human single-
RT   stranded DNA-binding protein phosphorylated by DNA-dependent protein
RT   kinase and Cdc2 kinase in vitro.";
RL   J. Biol. Chem. 272:12634-12641(1997).
RN   [22]
RP   ENZYME REGULATION.
RX   PubMed=9766667;
RA   Sarkaria J.N., Tibbetts R.S., Busby E.C., Kennedy A.P., Hill D.E.,
RA   Abraham R.T.;
RT   "Inhibition of phosphoinositide 3-kinase related kinases by the
RT   radiosensitizing agent wortmannin.";
RL   Cancer Res. 58:4375-4382(1998).
RN   [23]
RP   FUNCTION, INTERACTION WITH C1D, AND MUTAGENESIS OF LEU-1510 AND
RP   1516-GLU-LEU-1517.
RX   PubMed=9679063; DOI=10.1101/gad.12.14.2188;
RA   Yavuzer U., Smith G.C.M., Bliss T., Werner D., Jackson S.P.;
RT   "DNA end-independent activation of DNA-PK mediated via association
RT   with the DNA-binding protein C1D.";
RL   Genes Dev. 12:2188-2199(1998).
RN   [24]
RP   INTERACTION WITH ILF3.
RX   PubMed=9442054; DOI=10.1074/jbc.273.4.2136;
RA   Ting N.S.Y., Kao P.N., Chan D.W., Lintott L.G., Lees-Miller S.P.;
RT   "DNA-dependent protein kinase interacts with antigen receptor response
RT   element binding proteins NF90 and NF45.";
RL   J. Biol. Chem. 273:2136-2145(1998).
RN   [25]
RP   DNA-BINDING.
RX   PubMed=9435225; DOI=10.1073/pnas.95.2.525;
RA   Hammarsten O., Chu G.;
RT   "DNA-dependent protein kinase: DNA binding and activation in the
RT   absence of Ku.";
RL   Proc. Natl. Acad. Sci. U.S.A. 95:525-530(1998).
RN   [26]
RP   PHOSPHORYLATION OF XRCC5 AND XRCC6.
RX   PubMed=10026262; DOI=10.1021/bi982584b;
RA   Chan D.W., Ye R., Veillette C.J., Lees-Miller S.P.;
RT   "DNA-dependent protein kinase phosphorylation sites in Ku 70/80
RT   heterodimer.";
RL   Biochemistry 38:1819-1828(1999).
RN   [27]
RP   PHOSPHORYLATION OF PARP1.
RX   PubMed=10467406; DOI=10.1038/sj.onc.1202823;
RA   Ariumi Y., Masutani M., Copeland T.D., Mimori T., Sugimura T.,
RA   Shimotohno K., Ueda K., Hatanaka M., Noda M.;
RT   "Suppression of the poly(ADP-ribose) polymerase activity by DNA-
RT   dependent protein kinase in vitro.";
RL   Oncogene 18:4616-4625(1999).
RN   [28]
RP   PHOSPHORYLATION AT THR-2609; SER-2612; THR-2638 AND THR-2647.
RX   PubMed=12186630; DOI=10.1042/BJ20020973;
RA   Douglas P., Sapkota G.P., Morrice N., Yu Y., Goodarzi A.A., Merkle D.,
RA   Meek K., Alessi D.R., Lees-Miller S.P.;
RT   "Identification of in vitro and in vivo phosphorylation sites in the
RT   catalytic subunit of the DNA-dependent protein kinase.";
RL   Biochem. J. 368:243-251(2002).
RN   [29]
RP   INTERACTION WITH DCLRE1C.
RX   PubMed=11955432; DOI=10.1016/S0092-8674(02)00671-2;
RA   Ma Y., Pannicke U., Schwarz K., Lieber M.R.;
RT   "Hairpin opening and overhang processing by an Artemis/DNA-dependent
RT   protein kinase complex in nonhomologous end joining and V(D)J
RT   recombination.";
RL   Cell 108:781-794(2002).
RN   [30]
RP   PHOSPHORYLATION OF XRCC4.
RX   PubMed=12509254; DOI=10.1016/S1568-7864(01)00018-0;
RA   Hsu H.-L., Yannone S.M., Chen D.J.;
RT   "Defining interactions between DNA-PK and ligase IV/XRCC4.";
RL   DNA Repair 1:225-235(2002).
RN   [31]
RP   PHOSPHORYLATION AT THR-2609, MUTAGENESIS OF THR-2609, SUBCELLULAR
RP   LOCATION, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=12231622; DOI=10.1101/gad.1015202;
RA   Chan D.W., Chen B.P., Prithivirajsingh S., Kurimasa A., Story M.D.,
RA   Qin J., Chen D.J.;
RT   "Autophosphorylation of the DNA-dependent protein kinase catalytic
RT   subunit is required for rejoining of DNA double-strand breaks.";
RL   Genes Dev. 16:2333-2338(2002).
RN   [32]
RP   PHOSPHORYLATION OF WRN.
RX   PubMed=11889123; DOI=10.1074/jbc.M111523200;
RA   Karmakar P., Piotrowski J., Brosh R.M. Jr., Sommers J.A., Miller S.P.,
RA   Cheng W.H., Snowden C.M., Ramsden D.A., Bohr V.A.;
RT   "Werner protein is a target of DNA-dependent protein kinase in vivo
RT   and in vitro, and its catalytic activities are regulated by
RT   phosphorylation.";
RL   J. Biol. Chem. 277:18291-18302(2002).
RN   [33]
RP   FUNCTION, AND MUTAGENESIS OF THR-2638 AND THR-2647.
RX   PubMed=12649176;
RA   Soubeyrand S., Pope L., Pakuts B., Hache R.J.;
RT   "Threonines 2638/2647 in DNA-PK are essential for cellular resistance
RT   to ionizing radiation.";
RL   Cancer Res. 63:1198-1201(2003).
RN   [34]
RP   PHOSPHORYLATION OF POU2F1.
RX   PubMed=14612514;
RA   Schild-Poulter C., Shih A., Yarymowich N.C., Hache R.J.G.;
RT   "Down-regulation of histone H2B by DNA-dependent protein kinase in
RT   response to DNA damage through modulation of octamer transcription
RT   factor 1.";
RL   Cancer Res. 63:7197-7205(2003).
RN   [35]
RP   PHOSPHORYLATION OF H2AFX.
RX   PubMed=14627815; DOI=10.1093/nar/gkg921;
RA   Park E.-J., Chan D.W., Park J.-H., Oettinger M.A., Kwon J.;
RT   "DNA-PK is activated by nucleosomes and phosphorylates H2AX within the
RT   nucleosomes in an acetylation-dependent manner.";
RL   Nucleic Acids Res. 31:6819-6827(2003).
RN   [36]
RP   INTERACTION WITH DCLRE1C.
RX   PubMed=15071507; DOI=10.1038/sj.emboj.7600206;
RA   Pannicke U., Ma Y., Hopfner K.-P., Niewolik D., Lieber M.R.,
RA   Schwarz K.;
RT   "Functional and biochemical dissection of the structure-specific
RT   nuclease ARTEMIS.";
RL   EMBO J. 23:1987-1997(2004).
RN   [37]
RP   INTERACTION WITH DCLRE1C.
RX   PubMed=14744996; DOI=10.1084/jem.20031142;
RA   Poinsignon C., Moshous D., Callebaut I., de Chasseval R., Villey I.,
RA   de Villartay J.-P.;
RT   "The metallo-beta-lactamase/beta-CASP domain of Artemis constitutes
RT   the catalytic core for V(D)J recombination.";
RL   J. Exp. Med. 199:315-321(2004).
RN   [38]
RP   FUNCTION, AND INTERACTION WITH DCLRE1C.
RX   PubMed=15574326; DOI=10.1016/j.molcel.2004.11.017;
RA   Ma Y., Lu H., Tippin B., Goodman M.F., Shimazaki N., Koiwai O.,
RA   Hsieh C.-L., Schwarz K., Lieber M.R.;
RT   "A biochemically defined system for mammalian nonhomologous DNA end
RT   joining.";
RL   Mol. Cell 16:701-713(2004).
RN   [39]
RP   INTERACTION WITH DCLRE1C.
RX   PubMed=15456891; DOI=10.1128/MCB.24.20.9207-9220.2004;
RA   Zhang X., Succi J., Feng Z., Prithivirajsingh S., Story M.D.,
RA   Legerski R.J.;
RT   "Artemis is a phosphorylation target of ATM and ATR and is involved in
RT   the G2/M DNA damage checkpoint response.";
RL   Mol. Cell. Biol. 24:9207-9220(2004).
RN   [40]
RP   PHOSPHORYLATION OF DHX9.
RX   PubMed=14704337; DOI=10.1093/nar/gkg933;
RA   Zhang S., Schlott B., Goerlach M., Grosse F.;
RT   "DNA-dependent protein kinase (DNA-PK) phosphorylates nuclear DNA
RT   helicase II/RNA helicase A and hnRNP proteins in an RNA-dependent
RT   manner.";
RL   Nucleic Acids Res. 32:1-10(2004).
RN   [41]
RP   FUNCTION, SUBCELLULAR LOCATION, PHOSPHORYLATION AT SER-2056 AND
RP   THR-2609, AND DEPHOSPHORYLATION AT SER-2056 AND THR-2609.
RX   PubMed=14734805; DOI=10.1073/pnas.0307765100;
RA   Wechsler T., Chen B.P., Harper R., Morotomi-Yano K., Huang B.C.,
RA   Meek K., Cleaver J.E., Chen D.J., Wabl M.;
RT   "DNA-PKcs function regulated specifically by protein phosphatase 5.";
RL   Proc. Natl. Acad. Sci. U.S.A. 101:1247-1252(2004).
RN   [42]
RP   PHOSPHORYLATION OF H2AFX.
RX   PubMed=16046194; DOI=10.1016/j.dnarep.2005.06.005;
RA   Reitsema T., Klokov D., Banath J.P., Olive P.L.;
RT   "DNA-PK is responsible for enhanced phosphorylation of histone H2AX
RT   under hypertonic conditions.";
RL   DNA Repair 4:1172-1181(2005).
RN   [43]
RP   INTERACTION WITH DCLRE1C.
RX   PubMed=15811628; DOI=10.1016/j.dnarep.2005.02.001;
RA   Wang J., Pluth J.M., Cooper P.K., Cowan M.J., Chen D.J., Yannone S.M.;
RT   "Artemis deficiency confers a DNA double-strand break repair defect
RT   and Artemis phosphorylation status is altered by DNA damage and cell
RT   cycle progression.";
RL   DNA Repair 4:556-570(2005).
RN   [44]
RP   INTERACTION WITH DCLRE1C.
RX   PubMed=15936993; DOI=10.1016/j.dnarep.2005.04.013;
RA   Ma Y., Schwarz K., Lieber M.R.;
RT   "The Artemis:DNA-PKcs endonuclease cleaves DNA loops, flaps, and
RT   gaps.";
RL   DNA Repair 4:845-851(2005).
RN   [45]
RP   INTERACTION WITH XRCC5.
RX   PubMed=15758953; DOI=10.1038/nature03442;
RA   Falck J., Coates J., Jackson S.P.;
RT   "Conserved modes of recruitment of ATM, ATR and DNA-PKcs to sites of
RT   DNA damage.";
RL   Nature 434:605-611(2005).
RN   [46]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-3205, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [47]
RP   PHOSPHORYLATION OF XRCC1.
RX   PubMed=16397295; DOI=10.1093/nar/gkj409;
RA   Levy N., Martz A., Bresson A., Spenlehauer C., de Murcia G.,
RA   Menissier-de Murcia J.;
RT   "XRCC1 is phosphorylated by DNA-dependent protein kinase in response
RT   to DNA damage.";
RL   Nucleic Acids Res. 34:32-41(2006).
RN   [48]
RP   REVIEW.
RX   PubMed=15592499; DOI=10.1038/sj.onc.1208332;
RA   Collis S.J., DeWeese T.L., Jeggo P.A., Parker A.R.;
RT   "The life and death of DNA-PK.";
RL   Oncogene 24:949-961(2005).
RN   [49]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Embryonic kidney;
RX   PubMed=17525332; DOI=10.1126/science.1140321;
RA   Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III,
RA   Hurov K.E., Luo J., Bakalarski C.E., Zhao Z., Solimini N.,
RA   Lerenthal Y., Shiloh Y., Gygi S.P., Elledge S.J.;
RT   "ATM and ATR substrate analysis reveals extensive protein networks
RT   responsive to DNA damage.";
RL   Science 316:1160-1166(2007).
RN   [50]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-3205 AND SER-4026, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [51]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-3205, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [52]
RP   INVOLVEMENT IN IMD26, AND VARIANT IMD26 ARG-3062.
RX   PubMed=19075392; DOI=10.1172/JCI37141;
RA   van der Burg M., Ijspeert H., Verkaik N.S., Turul T., Wiegant W.W.,
RA   Morotomi-Yano K., Mari P.O., Tezcan I., Chen D.J., Zdzienicka M.Z.,
RA   van Dongen J.J., van Gent D.C.;
RT   "A DNA-PKcs mutation in a radiosensitive T-B- SCID patient inhibits
RT   Artemis activation and nonhomologous end-joining.";
RL   J. Clin. Invest. 119:91-98(2009).
RN   [53]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-893; SER-2612; SER-3205
RP   AND SER-4026, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [54]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-3205, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [55]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-117; LYS-828; LYS-1209;
RP   LYS-1970; LYS-2259; LYS-3241; LYS-3260; LYS-3621; LYS-3638 AND
RP   LYS-3642, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M.,
RA   Walther T.C., Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [56]
RP   INTERACTION WITH TTI1.
RX   PubMed=20810650; DOI=10.1101/gad.1934210;
RA   Hurov K.E., Cotta-Ramusino C., Elledge S.J.;
RT   "A genetic screen identifies the Triple T complex required for DNA
RT   damage signaling and ATM and ATR stability.";
RL   Genes Dev. 24:1939-1950(2010).
RN   [57]
RP   INTERACTION WITH TELO2.
RX   PubMed=20801936; DOI=10.1101/gad.1956410;
RA   Takai H., Xie Y., de Lange T., Pavletich N.P.;
RT   "Tel2 structure and function in the Hsp90-dependent maturation of mTOR
RT   and ATR complexes.";
RL   Genes Dev. 24:2019-2030(2010).
RN   [58]
RP   INTERACTION WITH TELO2 AND TTI1.
RX   PubMed=20427287; DOI=10.1074/jbc.M110.121699;
RA   Kaizuka T., Hara T., Oshiro N., Kikkawa U., Yonezawa K., Takehana K.,
RA   Iemura S., Natsume T., Mizushima N.;
RT   "Tti1 and Tel2 are critical factors in mammalian target of rapamycin
RT   complex assembly.";
RL   J. Biol. Chem. 285:20109-20116(2010).
RN   [59]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-3205 AND SER-4026, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [60]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [61]
RP   INTERACTION WITH BRAT1, AND PHOSPHORYLATION AT SER-2056.
RX   PubMed=22977523; DOI=10.3892/etm.2011.232;
RA   So E.Y., Ouchi T.;
RT   "Functional interaction of BRCA1/ATM-associated BAAT1 with the DNA-PK
RT   catalytic subunit.";
RL   Exp. Ther. Med. 2:443-447(2011).
RN   [62]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2612 AND SER-3205, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [63]
RP   SUBCELLULAR LOCATION [LARGE SCALE ANALYSIS].
RX   PubMed=22002106; DOI=10.1074/mcp.M111.013680;
RA   Ahmad Y., Boisvert F.M., Lundberg E., Uhlen M., Lamond A.I.;
RT   "Systematic analysis of protein pools, isoforms, and modifications
RT   affecting turnover and subcellular localization.";
RL   Mol. Cell. Proteomics 11:M111.013680.01-M111.013680.15(2012).
RN   [64]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-511; SER-687; SER-841;
RP   SER-1065; THR-2535; SER-2612; THR-2638; THR-2647; SER-2789; SER-3205;
RP   SER-3731; SER-3821 AND SER-4026, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [65]
RP   INTERACTION WITH SETX.
RX   PubMed=23149945; DOI=10.1128/MCB.01195-12;
RA   Yuce O., West S.C.;
RT   "Senataxin, defective in the neurodegenerative disorder ataxia with
RT   oculomotor apraxia 2, lies at the interface of transcription and the
RT   DNA damage response.";
RL   Mol. Cell. Biol. 33:406-417(2013).
RN   [66]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2612, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [67]
RP   UBIQUITINATION BY RNF144A.
RX   PubMed=24979766; DOI=10.1073/pnas.1323107111;
RA   Ho S.R., Mahanic C.S., Lee Y.J., Lin W.C.;
RT   "RNF144A, an E3 ubiquitin ligase for DNA-PKcs, promotes apoptosis
RT   during DNA damage.";
RL   Proc. Natl. Acad. Sci. U.S.A. 111:E2646-E2655(2014).
RN   [68]
RP   INTERACTION WITH NR4A3.
RX   PubMed=25852083; DOI=10.1093/cvr/cvv126;
RA   Medunjanin S., Daniel J.M., Weinert S., Dutzmann J., Burgbacher F.,
RA   Brecht S., Bruemmer D., Kaehne T., Naumann M., Sedding D.G.,
RA   Zuschratter W., Braun-Dullaeus R.C.;
RT   "DNA-dependent protein kinase (DNA-PK) permits vascular smooth muscle
RT   cell proliferation through phosphorylation of the orphan nuclear
RT   receptor NOR1.";
RL   Cardiovasc. Res. 106:488-497(2015).
RN   [69]
RP   SUBUNIT.
RX   PubMed=25941166; DOI=10.1038/cdd.2015.22;
RA   Craxton A., Somers J., Munnur D., Jukes-Jones R., Cain K.,
RA   Malewicz M.;
RT   "XLS (c9orf142) is a new component of mammalian DNA double-stranded
RT   break repair.";
RL   Cell Death Differ. 22:890-897(2015).
RN   [70]
RP   SUBUNIT.
RX   PubMed=25670504; DOI=10.1038/ncomms7233;
RA   Xing M., Yang M., Huo W., Feng F., Wei L., Jiang W., Ning S., Yan Z.,
RA   Li W., Wang Q., Hou M., Dong C., Guo R., Gao G., Ji J., Zha S.,
RA   Lan L., Liang H., Xu D.;
RT   "Interactome analysis identifies a new paralogue of XRCC4 in non-
RT   homologous end joining DNA repair pathway.";
RL   Nat. Commun. 6:6233-6233(2015).
RN   [71]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M.,
RA   Ayoub D., Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [72]
RP   INTERACTION WITH C9ORF142.
RX   PubMed=25574025; DOI=10.1126/science.1261971;
RA   Ochi T., Blackford A.N., Coates J., Jhujh S., Mehmood S., Tamura N.,
RA   Travers J., Wu Q., Draviam V.M., Robinson C.V., Blundell T.L.,
RA   Jackson S.P.;
RT   "DNA repair. PAXX, a paralog of XRCC4 and XLF, interacts with Ku to
RT   promote DNA double-strand break repair.";
RL   Science 347:185-188(2015).
RN   [73]
RP   VARIANTS [LARGE SCALE ANALYSIS] SER-6; ASN-263; ILE-333; ILE-420;
RP   SER-500; SER-605; LEU-649; SER-695; HIS-1136; VAL-1190; THR-1237;
RP   PHE-1279; MET-1447; GLY-1619; VAL-1680; VAL-1680; PRO-2023; GLN-2598;
RP   ASN-2810; CYS-2899; ALA-2941; ASP-3085; ASP-3149; SER-3198; SER-3201;
RP   GLU-3404; THR-3434; MET-3562; PHE-3584; ILE-3800; LEU-3836; SER-3936
RP   AND MET-3937.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [74]
RP   VARIANT IMD26 VAL-3574, AND CHARACTERIZATION OF VARIANT IMD26
RP   VAL-3574.
RX   PubMed=23722905; DOI=10.1172/JCI67349;
RA   Woodbine L., Neal J.A., Sasi N.K., Shimada M., Deem K., Coleman H.,
RA   Dobyns W.B., Ogi T., Meek K., Davies E.G., Jeggo P.A.;
RT   "PRKDC mutations in a SCID patient with profound neurological
RT   abnormalities.";
RL   J. Clin. Invest. 123:2969-2980(2013).
CC   -!- FUNCTION: Serine/threonine-protein kinase that acts as a molecular
CC       sensor for DNA damage. Involved in DNA non-homologous end joining
CC       (NHEJ) required for double-strand break (DSB) repair and V(D)J
CC       recombination. Must be bound to DNA to express its catalytic
CC       properties. Promotes processing of hairpin DNA structures in V(D)J
CC       recombination by activation of the hairpin endonuclease artemis
CC       (DCLRE1C). The assembly of the DNA-PK complex at DNA ends is also
CC       required for the NHEJ ligation step. Required to protect and align
CC       broken ends of DNA. May also act as a scaffold protein to aid the
CC       localization of DNA repair proteins to the site of damage. Found
CC       at the ends of chromosomes, suggesting a further role in the
CC       maintenance of telomeric stability and the prevention of
CC       chromosomal end fusion. Also involved in modulation of
CC       transcription. Recognizes the substrate consensus sequence [ST]-Q.
CC       Phosphorylates 'Ser-139' of histone variant H2AX/H2AFX, thereby
CC       regulating DNA damage response mechanism. Phosphorylates DCLRE1C,
CC       c-Abl/ABL1, histone H1, HSPCA, c-jun/JUN, p53/TP53, PARP1, POU2F1,
CC       DHX9, SRF, XRCC1, XRCC1, XRCC4, XRCC5, XRCC6, WRN, MYC and RFA2.
CC       Can phosphorylate C1D not only in the presence of linear DNA but
CC       also in the presence of supercoiled DNA. Ability to phosphorylate
CC       p53/TP53 in the presence of supercoiled DNA is dependent on C1D.
CC       Contributes to the determination of the circadian period length by
CC       antagonizing phosphorylation of CRY1 'Ser-588' and increasing CRY1
CC       protein stability, most likely through an indirect machanism.
CC       Interacts with CRY1 and CRY2; negatively regulates CRY1
CC       phosphorylation. {ECO:0000269|PubMed:12649176,
CC       ECO:0000269|PubMed:14734805, ECO:0000269|PubMed:15574326,
CC       ECO:0000269|PubMed:9679063}.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC   -!- ENZYME REGULATION: Inhibited by wortmannin. Activity of the enzyme
CC       seems to be attenuated by autophosphorylation.
CC       {ECO:0000269|PubMed:9766667}.
CC   -!- SUBUNIT: DNA-PK is a heterotrimer of PRKDC and the Ku p70/YRCC6-
CC       p86/XRCC5 dimer. Formation of this complex may be promoted by
CC       interaction with ILF3. Associates with the DNA-bound Ku
CC       heterodimer, but it can also bind to and be activated by free DNA.
CC       The DNA-PK heterotrimer associates with the LIG4-XRCC4 complex to
CC       form the core of the non-homologous end joining (NHEJ) complex.
CC       Additional components of the NHEJ complex include NHEJ1/XLF and
CC       C9ORF142/PAXX. Interacts with DNA-PKcs-interacting protein (KIP)
CC       with the region upstream the kinase domain. PRKDC alone also
CC       interacts with and phosphorylates DCLRE1C, thereby activating the
CC       latent endonuclease activity of this protein. Interacts with C1D.
CC       Interacts with TTI1 and TELO2. Interacts with CIB1. Interacts with
CC       SETX (PubMed:23149945). Interacts with NR4A3; the DNA-dependent
CC       protein kinase complex DNA-PK phosphorylates and activates NR4A3
CC       and prevents NR4A3 ubiquitinylation and degradation
CC       (PubMed:25852083). Interacts with BRAT1.
CC       {ECO:0000269|PubMed:11955432, ECO:0000269|PubMed:14744996,
CC       ECO:0000269|PubMed:15071507, ECO:0000269|PubMed:15456891,
CC       ECO:0000269|PubMed:15574326, ECO:0000269|PubMed:15758953,
CC       ECO:0000269|PubMed:15811628, ECO:0000269|PubMed:15936993,
CC       ECO:0000269|PubMed:20427287, ECO:0000269|PubMed:20801936,
CC       ECO:0000269|PubMed:20810650, ECO:0000269|PubMed:22977523,
CC       ECO:0000269|PubMed:23149945, ECO:0000269|PubMed:25574025,
CC       ECO:0000269|PubMed:25670504, ECO:0000269|PubMed:25852083,
CC       ECO:0000269|PubMed:25941166, ECO:0000269|PubMed:9372844,
CC       ECO:0000269|PubMed:9442054, ECO:0000269|PubMed:9679063}.
CC   -!- INTERACTION:
CC       O43918:AIRE; NbExp=2; IntAct=EBI-352053, EBI-1753081;
CC       P42575:CASP2; NbExp=4; IntAct=EBI-352053, EBI-520342;
CC       Q96SD1:DCLRE1C; NbExp=4; IntAct=EBI-352053, EBI-11694104;
CC       P14921:ETS1; NbExp=2; IntAct=EBI-352053, EBI-913209;
CC       P50549:ETV1; NbExp=2; IntAct=EBI-352053, EBI-3905068;
CC       P09629:HOXB7; NbExp=2; IntAct=EBI-352053, EBI-1248457;
CC       P17936:IGFBP3; NbExp=2; IntAct=EBI-352053, EBI-715709;
CC       Q9BPZ7:MAPKAP1; NbExp=2; IntAct=EBI-352053, EBI-749938;
CC       Q96RI1-2:NR1H4; NbExp=4; IntAct=EBI-352053, EBI-9640524;
CC       Q9HB75:PIDD1; NbExp=6; IntAct=EBI-352053, EBI-520427;
CC       P10276:RARA; NbExp=3; IntAct=EBI-352053, EBI-413374;
CC       P17947:SPI1; NbExp=2; IntAct=EBI-352053, EBI-2293548;
CC       P13010:XRCC5; NbExp=7; IntAct=EBI-352053, EBI-357997;
CC       P12956:XRCC6; NbExp=6; IntAct=EBI-352053, EBI-353208;
CC       P25490:YY1; NbExp=2; IntAct=EBI-352053, EBI-765538;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:12231622,
CC       ECO:0000269|PubMed:14734805, ECO:0000269|PubMed:22002106}.
CC       Nucleus, nucleolus {ECO:0000269|PubMed:22002106}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P78527-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P78527-2; Sequence=VSP_004708;
CC   -!- PTM: Autophosphorylated on Ser-2056, Thr-2609, Thr-2638 and Thr-
CC       2647. Ser-2056 and Thr-2609 are DNA damage-inducible
CC       phosphorylation sites (inducible with ionizing radiation, IR)
CC       dephosphorylated by PPP5C. Autophosphorylation induces a
CC       conformational change that leads to remodeling of the DNA-PK
CC       complex, requisite for efficient end processing and DNA repair.
CC       {ECO:0000269|PubMed:10026262, ECO:0000269|PubMed:10467406,
CC       ECO:0000269|PubMed:11889123, ECO:0000269|PubMed:12186630,
CC       ECO:0000269|PubMed:12231622, ECO:0000269|PubMed:12509254,
CC       ECO:0000269|PubMed:14612514, ECO:0000269|PubMed:14627815,
CC       ECO:0000269|PubMed:14704337, ECO:0000269|PubMed:14734805,
CC       ECO:0000269|PubMed:1597196, ECO:0000269|PubMed:16046194,
CC       ECO:0000269|PubMed:16397295, ECO:0000269|PubMed:2247066,
CC       ECO:0000269|PubMed:2507541, ECO:0000269|PubMed:8407951,
CC       ECO:0000269|PubMed:8464713, ECO:0000269|PubMed:8804412,
CC       ECO:0000269|PubMed:9139719, ECO:0000269|PubMed:9362500,
CC       ECO:0000269|PubMed:9363941}.
CC   -!- PTM: S-nitrosylated by GAPDH. {ECO:0000250}.
CC   -!- PTM: Polyubiquitinated by RNF144A, leading to proteasomal
CC       degradation. {ECO:0000269|PubMed:24979766}.
CC   -!- DISEASE: Immunodeficiency 26 with or without neurologic
CC       abnormalities (IMD26) [MIM:615966]: A form of severe combined
CC       immunodeficiency characterized by reduced or absent T and B cells,
CC       recurrent candidiasis, and lower respiratory tract infections.
CC       Some patients show dysmorphic features, severe growth failure,
CC       microcephaly, seizures, and impaired neurological functions.
CC       {ECO:0000269|PubMed:19075392, ECO:0000269|PubMed:23722905}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- SIMILARITY: Belongs to the PI3/PI4-kinase family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/prkdc/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U47077; AAB39925.5; -; mRNA.
DR   EMBL; U34994; AAC50210.3; -; mRNA.
DR   EMBL; AY316117; AAP69525.1; -; Genomic_DNA.
DR   EMBL; U63630; AAC52019.2; -; Genomic_DNA.
DR   EMBL; U90415; AAB51722.1; -; Genomic_DNA.
DR   EMBL; L27425; AAA79244.1; -; Genomic_DNA.
DR   EMBL; AB052953; BAB79635.1; -; Genomic_DNA.
DR   EMBL; U35835; AAA79184.1; -; mRNA.
DR   EMBL; AY030284; AAK40350.1; -; Genomic_DNA.
DR   EMBL; AB208860; BAD92097.1; -; mRNA.
DR   CCDS; CCDS75734.1; -. [P78527-2]
DR   CCDS; CCDS75735.1; -. [P78527-1]
DR   PIR; A57099; A57099.
DR   PIR; G02083; G02083.
DR   RefSeq; NP_001075109.1; NM_001081640.1. [P78527-2]
DR   RefSeq; NP_008835.5; NM_006904.6. [P78527-1]
DR   UniGene; Hs.491682; -.
DR   PDB; 5LUQ; X-ray; 4.30 A; A/B=2-2575, A/B=2774-4127.
DR   PDBsum; 5LUQ; -.
DR   ProteinModelPortal; P78527; -.
DR   SMR; P78527; -.
DR   BioGrid; 111577; 254.
DR   DIP; DIP-24186N; -.
DR   IntAct; P78527; 98.
DR   MINT; MINT-5006046; -.
DR   STRING; 9606.ENSP00000313420; -.
DR   BindingDB; P78527; -.
DR   ChEMBL; CHEMBL3142; -.
DR   DrugBank; DB00201; Caffeine.
DR   DrugBank; DB05210; SF1126.
DR   GuidetoPHARMACOLOGY; 2800; -.
DR   iPTMnet; P78527; -.
DR   PhosphoSitePlus; P78527; -.
DR   SwissPalm; P78527; -.
DR   BioMuta; PRKDC; -.
DR   DMDM; 38258929; -.
DR   SWISS-2DPAGE; P78527; -.
DR   EPD; P78527; -.
DR   MaxQB; P78527; -.
DR   PaxDb; P78527; -.
DR   PeptideAtlas; P78527; -.
DR   PRIDE; P78527; -.
DR   Ensembl; ENST00000314191; ENSP00000313420; ENSG00000253729. [P78527-1]
DR   Ensembl; ENST00000338368; ENSP00000345182; ENSG00000253729. [P78527-2]
DR   GeneID; 5591; -.
DR   KEGG; hsa:5591; -.
DR   UCSC; uc033bkh.1; human. [P78527-1]
DR   CTD; 5591; -.
DR   DisGeNET; 5591; -.
DR   GeneCards; PRKDC; -.
DR   HGNC; HGNC:9413; PRKDC.
DR   HPA; CAB005167; -.
DR   HPA; HPA035174; -.
DR   MalaCards; PRKDC; -.
DR   MIM; 600899; gene.
DR   MIM; 615966; phenotype.
DR   neXtProt; NX_P78527; -.
DR   OpenTargets; ENSG00000253729; -.
DR   Orphanet; 317425; Severe combined immunodeficiency due to DNA-PKcs deficiency.
DR   PharmGKB; PA33776; -.
DR   eggNOG; KOG0891; Eukaryota.
DR   eggNOG; COG5032; LUCA.
DR   GeneTree; ENSGT00830000128321; -.
DR   HOVERGEN; HBG053681; -.
DR   InParanoid; P78527; -.
DR   KO; K06642; -.
DR   OMA; LVEQFVF; -.
DR   OrthoDB; EOG091G0015; -.
DR   PhylomeDB; P78527; -.
DR   TreeFam; TF324494; -.
DR   Reactome; R-HSA-1834949; Cytosolic sensors of pathogen-associated DNA.
DR   Reactome; R-HSA-3270619; IRF3-mediated induction of type I IFN.
DR   Reactome; R-HSA-5693571; Nonhomologous End-Joining (NHEJ).
DR   Reactome; R-HSA-8866654; E3 ubiquitin ligases ubiquitinate target proteins.
DR   SIGNOR; P78527; -.
DR   ChiTaRS; PRKDC; human.
DR   GeneWiki; DNA-PKcs; -.
DR   GenomeRNAi; 5591; -.
DR   PRO; PR:P78527; -.
DR   Proteomes; UP000005640; Chromosome 8.
DR   Bgee; ENSG00000253729; -.
DR   ExpressionAtlas; P78527; baseline and differential.
DR   Genevisible; P78527; HS.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005958; C:DNA-dependent protein kinase-DNA ligase 4 complex; IDA:MGI.
DR   GO; GO:0031012; C:extracellular matrix; IDA:BHF-UCL.
DR   GO; GO:0016020; C:membrane; IDA:UniProtKB.
DR   GO; GO:0070419; C:nonhomologous end joining complex; IDA:UniProtKB.
DR   GO; GO:0000784; C:nuclear chromosome, telomeric region; IDA:BHF-UCL.
DR   GO; GO:0005730; C:nucleolus; IEA:UniProtKB-SubCell.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:CAFA.
DR   GO; GO:0043234; C:protein complex; IMP:CAFA.
DR   GO; GO:0032993; C:protein-DNA complex; IDA:CAFA.
DR   GO; GO:0005667; C:transcription factor complex; IDA:BHF-UCL.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004677; F:DNA-dependent protein kinase activity; IDA:MGI.
DR   GO; GO:0003690; F:double-stranded DNA binding; IDA:CAFA.
DR   GO; GO:0019899; F:enzyme binding; IEA:Ensembl.
DR   GO; GO:0019904; F:protein domain specific binding; IPI:CAFA.
DR   GO; GO:0004672; F:protein kinase activity; IDA:CACAO.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:BHF-UCL.
DR   GO; GO:0003723; F:RNA binding; IDA:UniProtKB.
DR   GO; GO:0008134; F:transcription factor binding; IPI:BHF-UCL.
DR   GO; GO:0002326; P:B cell lineage commitment; IEA:Ensembl.
DR   GO; GO:0007420; P:brain development; IEA:Ensembl.
DR   GO; GO:0008283; P:cell proliferation; IMP:BHF-UCL.
DR   GO; GO:0006464; P:cellular protein modification process; TAS:ProtInc.
DR   GO; GO:0032869; P:cellular response to insulin stimulus; IMP:BHF-UCL.
DR   GO; GO:0006302; P:double-strand break repair; IMP:BHF-UCL.
DR   GO; GO:0097681; P:double-strand break repair via alternative nonhomologous end joining; TAS:BHF-UCL.
DR   GO; GO:0006303; P:double-strand break repair via nonhomologous end joining; TAS:Reactome.
DR   GO; GO:0035234; P:ectopic germ cell programmed cell death; IEA:Ensembl.
DR   GO; GO:0007507; P:heart development; IEA:Ensembl.
DR   GO; GO:0033152; P:immunoglobulin V(D)J recombination; IEA:Ensembl.
DR   GO; GO:0008630; P:intrinsic apoptotic signaling pathway in response to DNA damage; IEA:Ensembl.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IMP:CACAO.
DR   GO; GO:2000773; P:negative regulation of cellular senescence; IEA:Ensembl.
DR   GO; GO:0002638; P:negative regulation of immunoglobulin production; IEA:Ensembl.
DR   GO; GO:0001933; P:negative regulation of protein phosphorylation; ISS:UniProtKB.
DR   GO; GO:2001229; P:negative regulation of response to gamma radiation; IEA:Ensembl.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; IDA:BHF-UCL.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; IEA:Ensembl.
DR   GO; GO:0048639; P:positive regulation of developmental growth; IEA:Ensembl.
DR   GO; GO:0048146; P:positive regulation of fibroblast proliferation; IEA:Ensembl.
DR   GO; GO:0002684; P:positive regulation of immune system process; IEA:Ensembl.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IMP:BHF-UCL.
DR   GO; GO:0032481; P:positive regulation of type I interferon production; TAS:Reactome.
DR   GO; GO:0002328; P:pro-B cell differentiation; IEA:Ensembl.
DR   GO; GO:0031648; P:protein destabilization; IEA:Ensembl.
DR   GO; GO:0006468; P:protein phosphorylation; IMP:CAFA.
DR   GO; GO:0016567; P:protein ubiquitination; TAS:Reactome.
DR   GO; GO:0042752; P:regulation of circadian rhythm; ISS:UniProtKB.
DR   GO; GO:0048660; P:regulation of smooth muscle cell proliferation; IMP:UniProtKB.
DR   GO; GO:0014823; P:response to activity; IEA:Ensembl.
DR   GO; GO:0010332; P:response to gamma radiation; IEA:Ensembl.
DR   GO; GO:0048511; P:rhythmic process; IEA:UniProtKB-KW.
DR   GO; GO:0072431; P:signal transduction involved in mitotic G1 DNA damage checkpoint; IMP:UniProtKB.
DR   GO; GO:0001756; P:somitogenesis; IEA:Ensembl.
DR   GO; GO:0048536; P:spleen development; IEA:Ensembl.
DR   GO; GO:0033077; P:T cell differentiation in thymus; IEA:Ensembl.
DR   GO; GO:0002360; P:T cell lineage commitment; IEA:Ensembl.
DR   GO; GO:0033153; P:T cell receptor V(D)J recombination; IEA:Ensembl.
DR   GO; GO:0016233; P:telomere capping; IMP:BHF-UCL.
DR   GO; GO:0048538; P:thymus development; IEA:Ensembl.
DR   Gene3D; 1.10.1070.11; -; 1.
DR   Gene3D; 1.25.10.10; -; 3.
DR   Gene3D; 1.25.40.10; -; 2.
DR   InterPro; IPR011989; ARM-like.
DR   InterPro; IPR016024; ARM-type_fold.
DR   InterPro; IPR003152; FATC_dom.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR012582; NUC194.
DR   InterPro; IPR000403; PI3/4_kinase_cat_dom.
DR   InterPro; IPR018936; PI3/4_kinase_CS.
DR   InterPro; IPR003151; PIK-rel_kinase_FAT.
DR   InterPro; IPR014009; PIK_FAT.
DR   InterPro; IPR011990; TPR-like_helical_dom.
DR   Pfam; PF02259; FAT; 1.
DR   Pfam; PF02260; FATC; 1.
DR   Pfam; PF08163; NUC194; 1.
DR   Pfam; PF00454; PI3_PI4_kinase; 1.
DR   SMART; SM01343; FATC; 1.
DR   SMART; SM01344; NUC194; 1.
DR   SMART; SM00146; PI3Kc; 1.
DR   SUPFAM; SSF48371; SSF48371; 8.
DR   SUPFAM; SSF56112; SSF56112; 2.
DR   PROSITE; PS51189; FAT; 1.
DR   PROSITE; PS51190; FATC; 1.
DR   PROSITE; PS00915; PI3_4_KINASE_1; 1.
DR   PROSITE; PS00916; PI3_4_KINASE_2; 1.
DR   PROSITE; PS50290; PI3_4_KINASE_3; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; ATP-binding;
KW   Biological rhythms; Complete proteome; Disease mutation; DNA damage;
KW   DNA recombination; DNA repair; DNA-binding; Kinase;
KW   Nucleotide-binding; Nucleus; Phosphoprotein; Polymorphism;
KW   Reference proteome; Repeat; SCID; Serine/threonine-protein kinase;
KW   TPR repeat; Transferase; Ubl conjugation.
FT   CHAIN         1   4128       DNA-dependent protein kinase catalytic
FT                                subunit.
FT                                /FTId=PRO_0000225598.
FT   REPEAT      288    323       HEAT 1.
FT   REPEAT     1004   1040       HEAT 2.
FT   REPEAT     1723   1756       TPR 1.
FT   DOMAIN     2883   3539       FAT. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00534}.
FT   REPEAT     2920   2948       TPR 2.
FT   REPEAT     2949   2982       TPR 3.
FT   DOMAIN     3747   4015       PI3K/PI4K. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00269}.
FT   DOMAIN     4096   4128       FATC. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00534, ECO:0000255|PROSITE-
FT                                ProRule:PRU00535}.
FT   REGION     1503   1538       Interaction with C1D.
FT                                {ECO:0000269|PubMed:9679063}.
FT   REGION     1503   1538       Leucine-zipper.
FT   REGION     2436   3212       KIP-binding.
FT   SITE       2020   2021       Cleavage; by caspase-3. {ECO:0000305}.
FT   MOD_RES     117    117       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES     511    511       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     687    687       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     828    828       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES     841    841       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     893    893       Phosphoserine.
FT                                {ECO:0000244|PubMed:19369195}.
FT   MOD_RES    1065   1065       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1209   1209       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES    1970   1970       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES    2056   2056       Phosphoserine; by autocatalysis.
FT                                {ECO:0000269|PubMed:14734805,
FT                                ECO:0000269|PubMed:22977523}.
FT   MOD_RES    2259   2259       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES    2535   2535       Phosphothreonine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES    2609   2609       Phosphothreonine; by autocatalysis.
FT                                {ECO:0000269|PubMed:12186630,
FT                                ECO:0000269|PubMed:12231622,
FT                                ECO:0000269|PubMed:14734805}.
FT   MOD_RES    2612   2612       Phosphoserine; by autocatalysis.
FT                                {ECO:0000244|PubMed:19369195,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000244|PubMed:24275569,
FT                                ECO:0000269|PubMed:12186630}.
FT   MOD_RES    2638   2638       Phosphothreonine; by autocatalysis.
FT                                {ECO:0000244|PubMed:23186163,
FT                                ECO:0000269|PubMed:12186630}.
FT   MOD_RES    2647   2647       Phosphothreonine; by autocatalysis.
FT                                {ECO:0000244|PubMed:23186163,
FT                                ECO:0000269|PubMed:12186630}.
FT   MOD_RES    2789   2789       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES    3205   3205       Phosphoserine.
FT                                {ECO:0000244|PubMed:17081983,
FT                                ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:19369195,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES    3241   3241       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES    3260   3260       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES    3621   3621       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES    3638   3638       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES    3642   3642       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES    3731   3731       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES    3821   3821       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES    4026   4026       Phosphoserine.
FT                                {ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:19369195,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:23186163}.
FT   VAR_SEQ    3799   3829       Missing (in isoform 2).
FT                                {ECO:0000303|Ref.10}.
FT                                /FTId=VSP_004708.
FT   VARIANT       6      6       A -> S (in dbSNP:rs8177999).
FT                                {ECO:0000269|PubMed:17344846,
FT                                ECO:0000269|Ref.3}.
FT                                /FTId=VAR_019179.
FT   VARIANT     263    263       K -> N (in a lung adenocarcinoma sample;
FT                                somatic mutation; dbSNP:rs758032015).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041602.
FT   VARIANT     333    333       M -> I (in dbSNP:rs8178017).
FT                                {ECO:0000269|PubMed:17344846,
FT                                ECO:0000269|Ref.3}.
FT                                /FTId=VAR_019180.
FT   VARIANT     420    420       V -> I (in dbSNP:rs55925466).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041603.
FT   VARIANT     500    500       G -> S (in a metastatic melanoma sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041604.
FT   VARIANT     605    605       T -> S (in dbSNP:rs8178033).
FT                                {ECO:0000269|PubMed:17344846,
FT                                ECO:0000269|Ref.3}.
FT                                /FTId=VAR_019181.
FT   VARIANT     649    649       F -> L (in dbSNP:rs55811715).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041605.
FT   VARIANT     680    680       I -> M (in dbSNP:rs8178040).
FT                                {ECO:0000269|Ref.3}.
FT                                /FTId=VAR_019182.
FT   VARIANT     695    695       P -> S (in dbSNP:rs8178046).
FT                                {ECO:0000269|PubMed:17344846,
FT                                ECO:0000269|Ref.3}.
FT                                /FTId=VAR_019183.
FT   VARIANT    1071   1071       N -> S (in dbSNP:rs8178070).
FT                                {ECO:0000269|Ref.3}.
FT                                /FTId=VAR_019184.
FT   VARIANT    1136   1136       R -> H (in a colorectal adenocarcinoma
FT                                sample; somatic mutation;
FT                                dbSNP:rs781401034).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041606.
FT   VARIANT    1190   1190       L -> V (in dbSNP:rs34598508).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041607.
FT   VARIANT    1237   1237       A -> T (in dbSNP:rs191531119).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041608.
FT   VARIANT    1279   1279       L -> F. {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041609.
FT   VARIANT    1314   1314       G -> V (in dbSNP:rs8178090).
FT                                {ECO:0000269|Ref.3}.
FT                                /FTId=VAR_019185.
FT   VARIANT    1447   1447       R -> M (in a lung squamous cell carcinoma
FT                                sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041610.
FT   VARIANT    1588   1588       D -> V (in dbSNP:rs8178104).
FT                                {ECO:0000269|Ref.3}.
FT                                /FTId=VAR_019186.
FT   VARIANT    1603   1603       Q -> H (in dbSNP:rs8178106).
FT                                {ECO:0000269|Ref.3}.
FT                                /FTId=VAR_019187.
FT   VARIANT    1619   1619       A -> G (in dbSNP:rs56182356).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041611.
FT   VARIANT    1680   1680       A -> V (in a metastatic melanoma sample;
FT                                somatic mutation; dbSNP:rs55735910).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041612.
FT   VARIANT    2023   2023       S -> P (in dbSNP:rs56042895).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041613.
FT   VARIANT    2095   2095       A -> V (in dbSNP:rs8178147).
FT                                {ECO:0000269|Ref.3}.
FT                                /FTId=VAR_019188.
FT   VARIANT    2598   2598       R -> Q (in dbSNP:rs55923149).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041614.
FT   VARIANT    2702   2702       K -> E (in dbSNP:rs8178178).
FT                                {ECO:0000269|Ref.3}.
FT                                /FTId=VAR_019189.
FT   VARIANT    2810   2810       S -> N (in a metastatic melanoma sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041615.
FT   VARIANT    2899   2899       R -> C (in dbSNP:rs4278157).
FT                                {ECO:0000269|PubMed:17344846,
FT                                ECO:0000269|Ref.3}.
FT                                /FTId=VAR_019190.
FT   VARIANT    2941   2941       G -> A (in a lung neuroendocrine
FT                                carcinoma sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041616.
FT   VARIANT    3062   3062       L -> R (in IMD26; shows increased long
FT                                palindromic (P)-nucleotide stretches in
FT                                the immunoglobulin coding joints
FT                                indicating a defect in hairpin opening
FT                                and insufficient DCLRE1C activation;
FT                                dbSNP:rs587777685).
FT                                {ECO:0000269|PubMed:19075392}.
FT                                /FTId=VAR_072569.
FT   VARIANT    3085   3085       E -> D (in dbSNP:rs56135402).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041617.
FT   VARIANT    3149   3149       G -> D (in dbSNP:rs8178208).
FT                                {ECO:0000269|PubMed:17344846,
FT                                ECO:0000269|Ref.3}.
FT                                /FTId=VAR_019191.
FT   VARIANT    3198   3198       T -> S (in dbSNP:rs55793951).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041618.
FT   VARIANT    3201   3201       P -> S (in dbSNP:rs8178216).
FT                                {ECO:0000269|PubMed:17344846,
FT                                ECO:0000269|Ref.3}.
FT                                /FTId=VAR_019192.
FT   VARIANT    3404   3404       G -> E (in dbSNP:rs8178225).
FT                                {ECO:0000269|PubMed:17344846,
FT                                ECO:0000269|Ref.3}.
FT                                /FTId=VAR_019193.
FT   VARIANT    3434   3434       I -> T (in dbSNP:rs7830743).
FT                                {ECO:0000269|PubMed:17344846,
FT                                ECO:0000269|Ref.3}.
FT                                /FTId=VAR_019194.
FT   VARIANT    3459   3459       N -> S (in dbSNP:rs8178228).
FT                                {ECO:0000269|Ref.3}.
FT                                /FTId=VAR_019195.
FT   VARIANT    3562   3562       L -> M (in dbSNP:rs8178232).
FT                                {ECO:0000269|PubMed:17344846,
FT                                ECO:0000269|Ref.3}.
FT                                /FTId=VAR_019196.
FT   VARIANT    3574   3574       A -> V (in IMD26; shows impaired function
FT                                in response to irradiation and a less
FT                                severe defect in V(D)J end-joining
FT                                suggesting that the missense mutation
FT                                retained some functional capacity;
FT                                consistent with a loss of function
FT                                mutation; dbSNP:rs587777686).
FT                                {ECO:0000269|PubMed:23722905}.
FT                                /FTId=VAR_072570.
FT   VARIANT    3584   3584       L -> F (in dbSNP:rs55866966).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041619.
FT   VARIANT    3702   3702       P -> L (in dbSNP:rs8178236).
FT                                /FTId=VAR_050534.
FT   VARIANT    3800   3800       L -> I (in dbSNP:rs56216442).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041620.
FT   VARIANT    3836   3836       P -> L (in dbSNP:rs8178245).
FT                                {ECO:0000269|PubMed:17344846,
FT                                ECO:0000269|Ref.3}.
FT                                /FTId=VAR_019197.
FT   VARIANT    3932   3932       M -> V (in dbSNP:rs8178248).
FT                                {ECO:0000269|Ref.3}.
FT                                /FTId=VAR_019198.
FT   VARIANT    3936   3936       G -> S (in dbSNP:rs55670423).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041621.
FT   VARIANT    3937   3937       V -> M (in dbSNP:rs56090750).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041622.
FT   MUTAGEN    1510   1510       L->P: Loss of interaction with C1D.
FT                                {ECO:0000269|PubMed:9679063}.
FT   MUTAGEN    1516   1517       EL->PD: Loss of interaction with C1D.
FT                                {ECO:0000269|PubMed:9679063}.
FT   MUTAGEN    2609   2609       T->A: Leads to radiation sensitivity and
FT                                impaired DSB joining. Gives rise to
FT                                reduced phosphorylation; when associated
FT                                with A-2612.
FT                                {ECO:0000269|PubMed:12231622}.
FT   MUTAGEN    2612   2612       S->A: Reduced phosphorylation; when
FT                                associated with A-2609.
FT   MUTAGEN    2638   2638       T->A: Alleviates phosphorylation, leaves
FT                                a fully active enzyme with compromised
FT                                cellular resistance to ionizing radiation
FT                                without affecting DNA end joining; when
FT                                associated with A-2647.
FT                                {ECO:0000269|PubMed:12649176}.
FT   MUTAGEN    2647   2647       T->A: Alleviates phosphorylation, leaves
FT                                a fully active enzyme with compromised
FT                                cellular resistance to ionizing radiation
FT                                without affecting DNA end joining; when
FT                                associated with A-2638.
FT                                {ECO:0000269|PubMed:12649176}.
FT   CONFLICT    405    405       D -> Y (in Ref. 2; AAC50210).
FT                                {ECO:0000305}.
FT   CONFLICT   1008   1008       A -> S (in Ref. 2; AAC50210).
FT                                {ECO:0000305}.
FT   CONFLICT   3660   3660       N -> T (in Ref. 8; AAA79184).
FT                                {ECO:0000305}.
FT   CONFLICT   3817   3817       L -> W (in Ref. 8; AAA79184).
FT                                {ECO:0000305}.
FT   CONFLICT   3862   3862       A -> P (in Ref. 8; AAA79184).
FT                                {ECO:0000305}.
FT   CONFLICT   4031   4031       I -> V (in Ref. 9; AAK40350).
FT                                {ECO:0000305}.
SQ   SEQUENCE   4128 AA;  469089 MW;  AC6E747FEB09F3E5 CRC64;
     MAGSGAGVRC SLLRLQETLS AADRCGAALA GHQLIRGLGQ ECVLSSSPAV LALQTSLVFS
     RDFGLLVFVR KSLNSIEFRE CREEILKFLC IFLEKMGQKI APYSVEIKNT CTSVYTKDRA
     AKCKIPALDL LIKLLQTFRS SRLMDEFKIG ELFSKFYGEL ALKKKIPDTV LEKVYELLGL
     LGEVHPSEMI NNAENLFRAF LGELKTQMTS AVREPKLPVL AGCLKGLSSL LCNFTKSMEE
     DPQTSREIFN FVLKAIRPQI DLKRYAVPSA GLRLFALHAS QFSTCLLDNY VSLFEVLLKW
     CAHTNVELKK AALSALESFL KQVSNMVAKN AEMHKNKLQY FMEQFYGIIR NVDSNNKELS
     IAIRGYGLFA GPCKVINAKD VDFMYVELIQ RCKQMFLTQT DTGDDRVYQM PSFLQSVASV
     LLYLDTVPEV YTPVLEHLVV MQIDSFPQYS PKMQLVCCRA IVKVFLALAA KGPVLRNCIS
     TVVHQGLIRI CSKPVVLPKG PESESEDHRA SGEVRTGKWK VPTYKDYVDL FRHLLSSDQM
     MDSILADEAF FSVNSSSESL NHLLYDEFVK SVLKIVEKLD LTLEIQTVGE QENGDEAPGV
     WMIPTSDPAA NLHPAKPKDF SAFINLVEFC REILPEKQAE FFEPWVYSFS YELILQSTRL
     PLISGFYKLL SITVRNAKKI KYFEGVSPKS LKHSPEDPEK YSCFALFVKF GKEVAVKMKQ
     YKDELLASCL TFLLSLPHNI IELDVRAYVP ALQMAFKLGL SYTPLAEVGL NALEEWSIYI
     DRHVMQPYYK DILPCLDGYL KTSALSDETK NNWEVSALSR AAQKGFNKVV LKHLKKTKNL
     SSNEAISLEE IRIRVVQMLG SLGGQINKNL LTVTSSDEMM KSYVAWDREK RLSFAVPFRE
     MKPVIFLDVF LPRVTELALT ASDRQTKVAA CELLHSMVMF MLGKATQMPE GGQGAPPMYQ
     LYKRTFPVLL RLACDVDQVT RQLYEPLVMQ LIHWFTNNKK FESQDTVALL EAILDGIVDP
     VDSTLRDFCG RCIREFLKWS IKQITPQQQE KSPVNTKSLF KRLYSLALHP NAFKRLGASL
     AFNNIYREFR EEESLVEQFV FEALVIYMES LALAHADEKS LGTIQQCCDA IDHLCRIIEK
     KHVSLNKAKK RRLPRGFPPS ASLCLLDLVK WLLAHCGRPQ TECRHKSIEL FYKFVPLLPG
     NRSPNLWLKD VLKEEGVSFL INTFEGGGCG QPSGILAQPT LLYLRGPFSL QATLCWLDLL
     LAALECYNTF IGERTVGALQ VLGTEAQSSL LKAVAFFLES IAMHDIIAAE KCFGTGAAGN
     RTSPQEGERY NYSKCTVVVR IMEFTTTLLN TSPEGWKLLK KDLCNTHLMR VLVQTLCEPA
     SIGFNIGDVQ VMAHLPDVCV NLMKALKMSP YKDILETHLR EKITAQSIEE LCAVNLYGPD
     AQVDRSRLAA VVSACKQLHR AGLLHNILPS QSTDLHHSVG TELLSLVYKG IAPGDERQCL
     PSLDLSCKQL ASGLLELAFA FGGLCERLVS LLLNPAVLST ASLGSSQGSV IHFSHGEYFY
     SLFSETINTE LLKNLDLAVL ELMQSSVDNT KMVSAVLNGM LDQSFRERAN QKHQGLKLAT
     TILQHWKKCD SWWAKDSPLE TKMAVLALLA KILQIDSSVS FNTSHGSFPE VFTTYISLLA
     DTKLDLHLKG QAVTLLPFFT SLTGGSLEEL RRVLEQLIVA HFPMQSREFP PGTPRFNNYV
     DCMKKFLDAL ELSQSPMLLE LMTEVLCREQ QHVMEELFQS SFRRIARRGS CVTQVGLLES
     VYEMFRKDDP RLSFTRQSFV DRSLLTLLWH CSLDALREFF STIVVDAIDV LKSRFTKLNE
     STFDTQITKK MGYYKILDVM YSRLPKDDVH AKESKINQVF HGSCITEGNE LTKTLIKLCY
     DAFTENMAGE NQLLERRRLY HCAAYNCAIS VICCVFNELK FYQGFLFSEK PEKNLLIFEN
     LIDLKRRYNF PVEVEVPMER KKKYIEIRKE AREAANGDSD GPSYMSSLSY LADSTLSEEM
     SQFDFSTGVQ SYSYSSQDPR PATGRFRRRE QRDPTVHDDV LELEMDELNR HECMAPLTAL
     VKHMHRSLGP PQGEEDSVPR DLPSWMKFLH GKLGNPIVPL NIRLFLAKLV INTEEVFRPY
     AKHWLSPLLQ LAASENNGGE GIHYMVVEIV ATILSWTGLA TPTGVPKDEV LANRLLNFLM
     KHVFHPKRAV FRHNLEIIKT LVECWKDCLS IPYRLIFEKF SGKDPNSKDN SVGIQLLGIV
     MANDLPPYDP QCGIQSSEYF QALVNNMSFV RYKEVYAAAA EVLGLILRYV MERKNILEES
     LCELVAKQLK QHQNTMEDKF IVCLNKVTKS FPPLADRFMN AVFFLLPKFH GVLKTLCLEV
     VLCRVEGMTE LYFQLKSKDF VQVMRHRDDE RQKVCLDIIY KMMPKLKPVE LRELLNPVVE
     FVSHPSTTCR EQMYNILMWI HDNYRDPESE TDNDSQEIFK LAKDVLIQGL IDENPGLQLI
     IRNFWSHETR LPSNTLDRLL ALNSLYSPKI EVHFLSLATN FLLEMTSMSP DYPNPMFEHP
     LSECEFQEYT IDSDWRFRST VLTPMFVETQ ASQGTLQTRT QEGSLSARWP VAGQIRATQQ
     QHDFTLTQTA DGRSSFDWLT GSSTDPLVDH TSPSSDSLLF AHKRSERLQR APLKSVGPDF
     GKKRLGLPGD EVDNKVKGAA GRTDLLRLRR RFMRDQEKLS LMYARKGVAE QKREKEIKSE
     LKMKQDAQVV LYRSYRHGDL PDIQIKHSSL ITPLQAVAQR DPIIAKQLFS SLFSGILKEM
     DKFKTLSEKN NITQKLLQDF NRFLNTTFSF FPPFVSCIQD ISCQHAALLS LDPAAVSAGC
     LASLQQPVGI RLLEEALLRL LPAELPAKRV RGKARLPPDV LRWVELAKLY RSIGEYDVLR
     GIFTSEIGTK QITQSALLAE ARSDYSEAAK QYDEALNKQD WVDGEPTEAE KDFWELASLD
     CYNHLAEWKS LEYCSTASID SENPPDLNKI WSEPFYQETY LPYMIRSKLK LLLQGEADQS
     LLTFIDKAMH GELQKAILEL HYSQELSLLY LLQDDVDRAK YYIQNGIQSF MQNYSSIDVL
     LHQSRLTKLQ SVQALTEIQE FISFISKQGN LSSQVPLKRL LNTWTNRYPD AKMDPMNIWD
     DIITNRCFFL SKIEEKLTPL PEDNSMNVDQ DGDPSDRMEV QEQEEDISSL IRSCKFSMKM
     KMIDSARKQN NFSLAMKLLK ELHKESKTRD DWLVSWVQSY CRLSHCRSRS QGCSEQVLTV
     LKTVSLLDEN NVSSYLSKNI LAFRDQNILL GTTYRIIANA LSSEPACLAE IEEDKARRIL
     ELSGSSSEDS EKVIAGLYQR AFQHLSEAVQ AAEEEAQPPS WSCGPAAGVI DAYMTLADFC
     DQQLRKEEEN ASVIDSAELQ AYPALVVEKM LKALKLNSNE ARLKFPRLLQ IIERYPEETL
     SLMTKEISSV PCWQFISWIS HMVALLDKDQ AVAVQHSVEE ITDNYPQAIV YPFIISSESY
     SFKDTSTGHK NKEFVARIKS KLDQGGVIQD FINALDQLSN PELLFKDWSN DVRAELAKTP
     VNKKNIEKMY ERMYAALGDP KAPGLGAFRR KFIQTFGKEF DKHFGKGGSK LLRMKLSDFN
     DITNMLLLKM NKDSKPPGNL KECSPWMSDF KVEFLRNELE IPGQYDGRGK PLPEYHVRIA
     GFDERVTVMA SLRRPKRIII RGHDEREHPF LVKGGEDLRQ DQRVEQLFQV MNGILAQDSA
     CSQRALQLRT YSVVPMTSRL GLIEWLENTV TLKDLLLNTM SQEEKAAYLS DPRAPPCEYK
     DWLTKMSGKH DVGAYMLMYK GANRTETVTS FRKRESKVPA DLLKRAFVRM STSPEAFLAL
     RSHFASSHAL ICISHWILGI GDRHLNNFMV AMETGGVIGI DFGHAFGSAT QFLPVPELMP
     FRLTRQFINL MLPMKETGLM YSIMVHALRA FRSDPGLLTN TMDVFVKEPS FDWKNFEQKM
     LKKGGSWIQE INVAEKNWYP RQKICYAKRK LAGANPAVIT CDELLLGHEK APAFRDYVAV
     ARGSKDHNIR AQEPESGLSE ETQVKCLMDQ ATDPNILGRT WEGWEPWM
//
